{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.clinicalstudies.in/sop-for-data-sharing-with-regulators-and-repositories”
},
“headline”: “SOP for Data Sharing with Regulators and Repositories”,
“description”: “This SOP defines procedures for sharing clinical trial data with regulators and repositories, ensuring compliance with FDA, EMA, WHO, CDSCO, and ICH GCP guidelines. It includes data anonymization, formatting, submission portals, timelines, and retention requirements.”,
“author”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”
},
“publisher”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”,
“logo”: {
“@type”: “ImageObject”,
“url”: “https://www.clinicalstudies.in/logo.png”
}
},
“datePublished”: “2025-08-26”,
“dateModified”: “2025-08-26”
}

Standard Operating Procedure for Data Sharing with Regulators and Repositories

Purpose

The purpose of this SOP is to define procedures for the secure and compliant sharing of clinical trial data with regulators and public repositories. Data sharing enhances transparency, facilitates regulatory review, and supports global scientific collaboration while protecting subject confidentiality.

Scope

This SOP applies to sponsors, CROs, regulatory affairs, data management, statisticians, and QA staff responsible for preparing and submitting trial data. It covers sharing of clinical study reports (CSRs), patient-level data, anonymized datasets, safety data, and genomic or specialty datasets with regulatory authorities and repositories.

Responsibilities

• Sponsor: Ensures data sharing obligations are met in line with regulatory requirements.
• Regulatory Affairs: Manages submissions through portals such as FDA CDER NextGen, EMA Data Sharing, and WHO ICTRP repositories.
• Data Management: Prepares anonymized datasets and metadata for submission.
• Statisticians: Generate analysis outputs and ensure integrity of statistical datasets.
• QA: Conducts QC checks on data packages prior to submission.

Accountability

The Sponsor’s Regulatory Head is accountable for ensuring accurate and timely data sharing with regulators and repositories. QA is accountable for verifying data integrity and compliance with GCP and privacy regulations.

Procedure

1. Planning
1.1 Develop Data Sharing Plan outlining obligations, datasets, repositories, and timelines.
1.2 Maintain Data Sharing Plan Log (Annexure-1).

2. Data Preparation
2.1 Extract data post-database lock.
2.2 Anonymize patient-level data in compliance with GDPR and HIPAA.
2.3 Prepare standardized datasets (e.g., CDISC SDTM, ADaM).
2.4 Maintain Data Preparation Log (Annexure-2).

3. Regulatory Submissions
3.1 Submit datasets through regulatory portals (FDA, EMA, CDSCO).
3.2 Upload supporting documents such as CSR, protocols, and SAP.
3.3 Maintain Regulatory Submission Log (Annexure-3).

4. Repository Sharing
4.1 Share trial data with WHO ICTRP and approved repositories where applicable.
4.2 Document repository submissions in Repository Sharing Log (Annexure-4).

5. Quality Control
5.1 QA verifies completeness, accuracy, and anonymization adequacy of data packages.
5.2 Document QC in Data Sharing QC Log (Annexure-5).

6. Archiving
6.1 Archive submitted datasets, logs, and confirmation receipts in TMF.
6.2 Retain in compliance with global archiving standards.

Abbreviations

• SOP: Standard Operating Procedure
• CSR: Clinical Study Report
• QA: Quality Assurance
• CRO: Contract Research Organization
• TMF: Trial Master File
• CDISC: Clinical Data Interchange Standards Consortium
• SDTM: Study Data Tabulation Model
• ADaM: Analysis Data Model
• EMA: European Medicines Agency
• FDA: Food and Drug Administration
• WHO: World Health Organization
• CDSCO: Central Drugs Standard Control Organization
• HIPAA: Health Insurance Portability and Accountability Act
• GDPR: General Data Protection Regulation

Documents

1. Data Sharing Plan Log (Annexure-1)
2. Data Preparation Log (Annexure-2)
3. Regulatory Submission Log (Annexure-3)
4. Repository Sharing Log (Annexure-4)
5. Data Sharing QC Log (Annexure-5)

References

• ICH E6(R2/R3) – Data Sharing Requirements
• FDA – Study Data Standards and Submissions
• EMA – Policy on Clinical Data Publication
• CDSCO – Clinical Data Sharing Regulations
• WHO – Data Sharing Standards

Version: 1.0

Approval Section

Annexures

Annexure-1: Data Sharing Plan Log

Annexure-2: Data Preparation Log

Annexure-3: Regulatory Submission Log

Annexure-4: Repository Sharing Log

Annexure-5: Data Sharing QC Log

Revision History

For more SOPs visit: Pharma SOP

{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.Clinicalstudies.in/SOP-for-Genetic-Sample-Consent-and-Data-Use”
},
“headline”: “SOP for Genetic Sample Consent and Data Use in Clinical Trials”,
“description”: “This SOP describes regulatory-compliant procedures for obtaining informed consent for genetic sample collection, storage, and data use in clinical trials, aligned with ICH GCP, FDA, EMA, CDSCO, and WHO guidelines.”,
“author”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”
},
“publisher”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”,
“logo”: {
“@type”: “ImageObject”,
“url”: “https://www.clinicalstudies.in/logo.png”
}
},
“datePublished”: “2025-08-26”,
“dateModified”: “2025-08-26”
}

Standard Operating Procedure for Genetic Sample Consent and Data Use

Purpose

The purpose of this SOP is to provide detailed instructions for obtaining informed consent for genetic sample collection, storage, and data use in clinical trials. It also covers participant rights, withdrawal procedures, and regulatory compliance related to the use of genetic material and associated data.

Scope

This SOP applies to all investigators, study staff, biobank managers, and data protection officers involved in trials where genetic samples (blood, saliva, tissue, DNA/RNA) are collected. It covers both primary and secondary use of genetic material and applies to international multi-center trials.

Responsibilities

• Principal Investigator (PI): Ensures that participants are fully informed of genetic sample use and that consent is obtained before collection.
• Study Coordinator: Manages sample labeling, anonymization/pseudonymization, and storage processes.
• Data Protection Officer: Ensures compliance with data privacy regulations (GDPR, HIPAA, CDSCO rules).
• Ethics Committee/IRB: Reviews and approves consent language and safeguards for genetic data use.
• Quality Assurance Officer: Verifies compliance during audits and inspections.

Accountability

The Principal Investigator and sponsor are accountable for ensuring that genetic sample consent procedures comply with ethical standards, participant rights, and applicable regulatory guidelines. Improper consent or misuse of genetic data may result in ethical violations and legal liability.

Procedure

1. Preparation of Genetic Consent Form
Draft a separate section in the Informed Consent Form (ICF) explaining genetic sample collection, use, and data storage.
Include details of possible future use, anonymization, data sharing, and retention.
Obtain EC/IRB approval for consent form before use.

2. Participant Information and Counseling
Provide clear explanation of why genetic samples are collected and how they will be used.
Discuss risks such as privacy breaches, potential misuse, or incidental findings.
Inform participants of their right to decline genetic testing while still participating in the trial (if applicable).

3. Obtaining Consent
Obtain written consent for genetic sample collection and use.
Obtain specific consent for secondary use of genetic material in future studies.
Record participant’s preferences regarding data sharing with international repositories.

4. Sample Handling and Anonymization
Label samples with coded identifiers, not participant names.
Maintain a linkage file securely stored and accessible only to authorized personnel.
Follow biosafety procedures for collection, storage, and transport.

5. Data Privacy and Security
Store genetic data in encrypted systems with access controls.
Comply with applicable regulations such as GDPR, HIPAA, and CDSCO privacy laws.
Ensure cross-border data transfers meet international standards.

6. Withdrawal of Consent
Allow participants to withdraw consent for genetic sample use at any stage.
Destroy or anonymize withdrawn samples where feasible.
Document withdrawal in Consent Documentation Log.

7. Record Keeping
File consent forms in Trial Master File (TMF).
Maintain sample tracking logs, data storage logs, and destruction records.

Abbreviations

• SOP: Standard Operating Procedure
• PI: Principal Investigator
• ICF: Informed Consent Form
• EC: Ethics Committee
• IRB: Institutional Review Board
• GDPR: General Data Protection Regulation
• HIPAA: Health Insurance Portability and Accountability Act
• TMF: Trial Master File

Documents

1. Genetic Sample Consent Form (Annexure-1)
2. Sample Tracking Log (Annexure-2)
3. Data Use Agreement Template (Annexure-3)

References

• ICH E6(R2) – Good Clinical Practice
• US FDA – Genomic Research Guidance
• EMA Clinical Trial Regulation (EU No. 536/2014)
• CDSCO Clinical Trial Rules, 2019
• WHO – Guidance on Ethics in Health Research

Version: 1.0

Approval Section

Annexures

Annexure-1: Genetic Sample Consent Form

Annexure-2: Sample Tracking Log

Annexure-3: Data Use Agreement Template

Revision History

For more SOPs visit: Pharma SOP